Xenon Pharmaceuticals (XENE) Tops Q1 EPS by 10c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Xenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 21, 2020 4:01 PM EDTProgress Reported in Both Proprietary and Partnered Neurology Clinical ProgramsÂ
Additional FDA Feedback Supports Commencement of XEN496 Phase 3 Clinical Trial in 2020
Conference Call at 4:30 pm ET Today
BURNABY, British Columbia, May 21, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurology-focused biopharmaceutical company, today reported its financial results for first quarter ended March 31, 2020 and provided a corporate update.
Dr. Simon Pimstone, Xenons Chief Executive Officer,... More
